MLECW — Moolec Science S.A.

Moolec Science Q4 2024 Earnings Call Summary

1. Key Financial Results and Metrics

• Normalized Revenues: Increased to $5.8 million in FY2024 from approximately $1 million in FY2023, attributed to the consolidation of the soy product ingredient business.
• Cost of Sales: Rose to $4.5 million in FY2024 from $1 million in FY2023, aligning with revenue growth.
• Expenses: SG&A and R&D expenses increased by $3.1 million to $9.3 million, primarily due to non-cash items and consolidation costs.
• Cash Utilization: Increased to $9.3 million in FY2024 from $7.5 million in FY2023.
• Cash Position: Approximately $5.4 million as of Q4 2024, bolstered by the purchase of 15,000 tons of HB4 soybean through a convertible note.

2. Strategic Updates and Business Highlights

• Regulatory Achievements: Received USDA approval for Piggy Sooy, marking a significant milestone as the first company in the industry to achieve such approval.
• Product Development: Successful establishment of a molecular biology lab in Texas and significant advancements in the Piggy Sooy product, with animal protein expression levels stabilizing at around 20%.
• Commercialization Efforts: Initiated field trials for Piggy Sooy in multiple states and began planting Glaso seeds, with contracts secured for production.
• Partnerships: Signed an R&D collaboration agreement with Bunge to improve safflower varieties, enhancing productivity for specific applications.

3. Forward Guidance and Outlook

• Fiscal Year 2025 Expectations: Anticipate commercialization of Glaso, targeting it to contribute approximately 15% of total revenues, with expectations for gradual growth in subsequent years.
• Operational Focus: Plans to enhance upstream and downstream yields, scale seed inventory, and continue regulatory progress for Piggy Sooy, aiming for commercialization by 2027-2028.
• Sales and Marketing Expansion: Intent to increase visibility through industry shows and expand the sales team to capture market opportunities.

4. Bad News, Challenges, or Points of Concern

• Increased Expenses: Rising SG&A and R&D expenses could pressure margins if revenue growth does not keep pace.
• Cash Utilization: Increased cash burn may raise concerns about financial sustainability in the short term.
• Regulatory Risks: While progress has been made, ongoing regulatory approvals for Piggy Sooy and other products remain a potential risk.
• Market Competition: The competitive landscape for plant-based proteins and oils is intensifying, necessitating strong differentiation and marketing efforts.

5. Notable Q&A Insights

• Offtake Agreements: Management confirmed the signing of a three-year offtake agreement for Glaso with a major global CPG company, emphasizing the significance of this partnership for market entry.
• Market Applications: Glaso is positioned for dietary supplements, nutritional beverages, and pet food, with expectations for strong demand due to its high GLA concentration.
• Future Partnerships: While no additional offtake agreements were signed recently, management is optimistic about securing more contracts as they ramp up production and marketing efforts.
• Investor Relations: Management acknowledged the need for improved communication and awareness of their technology among potential investors and industry stakeholders, emphasizing their commitment to transparency and education.

Overall, Moolec Science has made significant strides in product development and regulatory approvals, positioning itself for growth in FY2025, despite facing challenges related to expenses and market competition.